AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35341647
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD, 2.5x10^10 viral particles)
Trial: 33780274
Drug: Alpelisib 300
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib 300 mg daily plus fulvestrant 500 mg
Trial: 32147925
Drug: Water-soluble CBD
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble CBD powder (30 mg)
Trial: 32147925
Drug: Lipid-soluble CBD
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-soluble CBD powder (30 mg)
Trial: 32147925
Drug: CBD exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD exposure (both formulations)
Trial: 34324113
Drug: Post-mastectomy radiation
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-mastectomy radiation therapy (PMRT)
Trial: 34307194
Drug: Adjunctive COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive COX-2 inhibitor (etoricoxib)
Trial: 34307194
Drug: Standard TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TB treatment without COX-2 inhibitor
Trial: 32114523
Drug: Drospirenone 4
RxNorm normalized name: drospirenone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 4 mg film-coated tablet, 24 days active treatment followed by 4 days placebo, for 13 cycles of 28 days each
Trial: 36423240
Drug: PCC4 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCC4 (30 units/kg) administered intraoperatively
Trial: 32348263
Drug: Pedometer app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pedometer app with structured information delivery, personalized physical activity prescription, and follow-up on number of steps per day
Trial: 32348263
Drug: Pedometer app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pedometer app with daily walking goal of 10,000 steps
Trial: 36112590
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin coconut oil (EVCO) 25 g
Trial: 36112590
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin olive oil (EVOO) 25 g
Trial: 34075589
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg intravenous, weeks 0, 4, and 8)
Trial: 34425071
Drug: Selonsertib 2
RxNorm normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selonsertib 2 mg
Trial: 32147362
Drug: Selonsertib 6
RxNorm normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selonsertib 6 mg
Trial: 32147362
Drug: Selonsertib 18
RxNorm normalized name: Selonsertib
DrugBank: Selonsertib (DB14916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selonsertib 18 mg
Trial: 33982167
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) using glass ionomer cement (KetacTM Molar Easymix)
Trial: 33419872
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (PCV9)
Trial: 33970042
Drug: CaneCPI-5 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaneCPI-5 (0.1 mg/mL)
Trial: 32046669
Drug: Online intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online intervention based on Cognitive Behavioral Therapy (n=120)
Trial: 33220397
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (AA) with FOLFOX x6 cycles prior to high dose rate brachytherapy (HDRBT) and surgery plus adjuvant FOLFOX x6 cycles
Trial: 33499569
Drug: Fractional carbon
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional carbon dioxide laser combined with autologous fat injection
Trial: 36214144
Drug: Basal analgesia:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal analgesia: midazolam (1 mg), fentanyl (0.05 mg), dexketoprofen (50 mg)
Trial: 34022103
Drug: Lactobacilli (SynForU‐HerCare;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli (SynForU‐HerCare; two capsules/day of 9·5 log CFU per capsule)
Trial: 35527324
Drug: Morphine-based patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-based patient-controlled analgesia (PCA)
Trial: 33142467
Drug: 300 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/kg SB
Trial: 33142467
Drug: 600 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/kg SB
Trial: 33142467
Drug: 1,200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg/kg SB
Trial: 35786581
Drug: Preemptive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive group (n=50) - administered 600 mg of ibuprofen 1 hour before the procedure
Trial: 35786581
Drug: Preventive group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive group (n=50) - administered placebo preoperatively
Trial: 34133859
Drug: Targeted normothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted normothermia with early treatment of fever (body temperature, ≥37.8°C)
Trial: 32430027
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) treatment, 1 to 3 treatment cycles
Trial: 37045502
Drug: Genetic-guided P2Y12
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic-guided P2Y12 inhibitor therapy (ticagrelor for LOF carriers, clopidogrel for noncarriers)
Trial: 37045502
Drug: Conventional clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional clopidogrel therapy
Trial: 32497605
Drug: Oxygen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supplementation (10 L/min) for long durations (≥75th percentile)
Trial: 32497605
Drug: Oxygen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supplementation (10 L/min) for short durations (<75th percentile)
Trial: 35605429
Drug: PRI-724 (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRI-724 (280 mg/m2/4 h) administered intravenously twice weekly for 12 weeks
Trial: 33631372
Drug: Cognitive Reserve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Reserve EnhAncement ThErapy (CREATE)
Trial: 33631372
Drug: Community comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community comparison group (CC)
Trial: 32472357
Drug: Ambrisentan 10
RxNorm normalized name: ambrisentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 10 mg (generic product)
Trial: 32472357
Drug: Volibris® (ambrisentan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volibris® (ambrisentan) 10 mg (reference product)
Trial: 32472357
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Ambrisentan 10 mg and Volibris® 10 mg)
Trial: 34363764
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of 0.5% bupivacaine hydrochloride + 1 mL/4 mg dexamethasone (Group A1)
Trial: 34363764
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine hydrochloride + 1 mL/4 mg dexamethasone (Group B1)
Trial: 34363764
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of 0.5% bupivacaine hydrochloride (Group A)
Trial: 34011358
Drug: Artefenomel (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artefenomel (800 mg) plus ferroquine (400 mg to 1200 mg)
Trial: 35510765
Drug: Hydroquinone 4%/ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinone 4%/ascorbic acid 3% cream (HC)
Trial: 32106548
Drug: Standardized bilberry
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized bilberry extract (SBE) 240 mg once daily for 12 weeks
Trial: 34002910
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) treatment
Trial: 32422871
Drug: Campus forest
RxNorm normalized name: Fortesta
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Campus forest therapy program
Trial: 35059248
Drug: LMET +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMET + DPP4i treatment (low-dose metformin 750 mg/day + vildagliptin 100 mg/day)
Trial: 35059248
Drug: HMET treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMET treatment (high-dose metformin 1500 mg/day)
Trial: 37550942
Drug: ozanimod treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ozanimod treatment
Trial: 35103905
Drug: Locally produced
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally produced ready‐to‐use therapeutic food (L‐RUTF)
Trial: 35183157
Drug: Balance Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance Body Tape (BBT) treatment for 3 weeks
Trial: 33256758
Drug: Single screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single screening and treatment (SST) strategy using malaria rapid diagnostic tests (RDT)
Trial: 36130753
Drug: Combined low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined low energy diet (800-900 kcal/day) with meal replacement products and supervised exercise training (aerobic and resistance) three times weekly during the intensive phase (12 weeks)
Trial: 32345700
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist intervention targeting drug-related problems (DRPs), initiated within a week of discharge, involving medical chart reviews, phone interviews, and medication reviews.
Trial: 34384499
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 240, 480, 960, or 1440 mg ES16001 (SAD study)
Trial: 34384499
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily doses of 480 or 960 mg ES16001 for 5 days (MAD study)
Trial: 33522565
Drug: Individualized exercise
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized exercise program (2 daily sessions of 20 minutes for 5-7 days)
Trial: 33392869
Drug: Subharmonic imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subharmonic imaging (SHI) using Sonazoid contrast agent
Trial: 32090660
Drug: Neurofeedback (NFB)
RxNorm normalized name: NFBA
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neurofeedback (NFB) treatment, 40 sessions targeting very slow cortical potential range, addressing inhibitory deficits through right and left prefrontal training.
Trial: 32090660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sham treatment).
Trial: 35568668
Drug: Peri-urethral bulking
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-urethral bulking injections (PBI) with polydimethylsiloxane Urolastic (PDMS-U)
Trial: 33740415
Drug: Aggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive hydration plus rectal NSAIDs (100 mg diclofenac or indomethacin); aggressive hydration comprised 20 mL/kg intravenous Ringer's lactate solution within 60 min from the start of ERCP, followed by 3 mL/kg per h for 8 h.
Trial: 33740415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received rectal NSAIDs (100 mg diclofenac or indomethacin) alone with normal intravenous saline (maximum of 1·5 mL/kg per h and 3 L per 24 h).
Trial: 33740415
Drug: Aggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive hydration plus rectal NSAIDs
Trial: 33740415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rectal NSAIDs alone)
Trial: 32584199
Drug: Clinical trials
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical trials for therapeutics and vaccine development
Trial: 32027191
Drug: Birthweight ≥1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birthweight ≥1000 g
Trial: 33946255
Drug: PAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP treatment with enhanced support from a physiotherapist
Trial: 34506596
Drug: Equol supplement
RxNorm normalized name: equol, (+-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equol supplement
Trial: 34864830
Drug: Mindfulness mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness mobile application (Headspace) used daily for at least 6 weeks
Trial: 32090464
Drug: Intraperitoneal local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal local anaesthetic (IPLA) with ropivacaine instillation followed by a 3-day infusion.
Trial: 32090464
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving 0.9% saline solution.
Trial: 33675342
Drug: VA-fortified rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VA-fortified rice (500 µg RAEs/d)
Trial: 36030153
Drug: Normoglycemia checklist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycemia checklist applied preoperatively, intraoperatively, and postoperatively with continuous insulin infusion to maintain blood glucose levels between 80 to 150 mg/dl for 48 hours postoperative
Trial: 35436142
Drug: Mannitol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (20 g)
Trial: 34359097
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 92/22 μg
Trial: 32540725
Drug: Sinacurcumin® 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinacurcumin® 80 mg daily
Trial: 34235862
Drug: No TB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TB treatment
Trial: 36192209
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC): plasmapheresis/intravenous immunoglobulin
Trial: 35802483
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (1.5 μg/kg)
Trial: 35802483
Drug: PO acetaminophen/hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO acetaminophen/hydrocodone (0.15 mg/kg)
Trial: 32488435
Drug: Advanced pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced pneumatic compression device (APCD) used once per day (instead of prescribed twice per day).
Trial: 34758887
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) induction, n = 20
Trial: 34758887
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) induction, n = 17
Trial: 34787383
Drug: Direct osteopathic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct osteopathic primary care sports medicine intervention (n=18)
Trial: 35039206
Drug: Topical antioxidants
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antioxidants (AOx)
Trial: 33089293
Drug: Bio-Oss bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-Oss bone powder with Heal-All Oral repair membrane
Trial: 32650814
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instruction (OHI)
Trial: 32361265
Drug: Necuparanib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib (5 mg/kg subcutaneous injection once daily)
Trial: 33668849
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day algal docosahexaenoic acid (DHA)
Trial: 33668849
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two microencapsulated soy and corn oil tablets)
Trial: 35176038
Drug: Evocalcet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet with intravenous vitamin D receptor activator (low dose < 1.5 μg)
Trial: 35176038
Drug: Evocalcet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet with intravenous vitamin D receptor activator (high dose ≥ 1.5 μg)
Trial: 35176038
Drug: Evocalcet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet with intravenous vitamin D receptor activator (all groups)
Trial: 34721802
Drug: General Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Medicine (GM) rotation
Trial: 32964624
Drug: FA‐treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA‐treatment with in-session exposure (FA‐ISE)
Trial: 32964624
Drug: FA‐treatment without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA‐treatment without in-session exposure (FA)
Trial: 35728577
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + L‐PRF
Trial: 35300258
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy program (CPT)
Trial: 32503657
Drug: Favipiravir 1600mg
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir 1600mg each dose, twice a day on the 1st day; 600mg each dose, twice a day from the 2nd to the 7th day, for a maximum of 14 days plus routine treatment for COVID-19.
Trial: 32503657
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment for patients with COVID-19, including oxygen therapy and drugs that reduce phlegm and relieve cough.
Trial: 36281496
Drug: ORMD‐0801 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 8 mg BID
Trial: 36281496
Drug: ORMD‐0801 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 8 mg QD
Trial: 36281496
Drug: ORMD‐0801 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 32 mg QD
Trial: 36281496
Drug: ORMD‐0801 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 32 mg BID
Trial: 36281496
Drug: ORMD‐0801 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 16 mg QD
Trial: 36281496
Drug: ORMD‐0801 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 16 mg BID
Trial: 36281496
Drug: ORMD‐0801 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORMD‐0801 32 mg TID
Trial: 34711436
Drug: MF59-adjuvanted, cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c), 7.5 µg hemagglutinin antigen per dose
Trial: 34711436
Drug: MF59-adjuvanted, cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine (aH5N1c)
Trial: 34635114
Drug: Carglumic acid
RxNorm normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carglumic acid with standard treatment
Trial: 32278779
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid treatment
Trial: 36168738
Drug: NeuFlex implant
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NeuFlex implant
Trial: 36168738
Drug: Integra implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integra implant
Trial: 33429977
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g xylitol
Trial: 33429977
Drug: 17 g
RxNorm normalized name: lancets 17 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 g xylitol
Trial: 33429977
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g xylitol
Trial: 33573042
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA supplementation (142 mg EPA, 267 mg DHA, 12 mg vitamin E, 5 µg vitamin D, six capsules twice a day for three weeks)